CytoMed Therapeutics Limited Ordinary Shares (GDTC) — Financial Flexibility Index
CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a Financial Flexibility Index of -1.55x as of December 2025. Free cash flow of $-1.75 Million (operating CF $-2.05 Million minus capex $297.96K) represents -2% of total liabilities ($1.13 Million). Check tangible equity quality of CytoMed Therapeutics Limited Ordinary Sh to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
CytoMed Therapeutics Limited Ordinary Shares Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for CytoMed Therapeutics Limited Ordinary Shares across 7 annual periods. For the full cash flow conversion analysis, see CytoMed Therapeutics Limited Ordinary Sh cash flow conversion.
Annual Financial Flexibility Index for CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
Year-by-year free cash flow to debt coverage for CytoMed Therapeutics Limited Ordinary Shares. Explore CytoMed Therapeutics Limited Ordinary Sh (GDTC) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.65x | $-2.99 Million | $-3.70 Million | $1.13 Million | ▼ -106.9% |
| 2024 | -1.28x | $-1.31 Million | $-2.71 Million | $1.02 Million | ▲ +58.6% |
| 2023 | -3.09x | $-3.48 Million | $-3.54 Million | $1.13 Million | ▼ -1449.8% |
| 2022 | -0.20x | $-928.92K | $-1.40 Million | $4.66 Million | ▲ +38.5% |
| 2021 | -0.32x | $-1.13 Million | $-1.72 Million | $3.50 Million | ▼ -61.5% |
| 2020 | -0.20x | $-671.13K | $-916.39K | $3.35 Million | ▼ -137.1% |
| 2019 | 0.54x | $544.52K | $-640.52K | $1.01 Million | — |